Bay­er boost­ed as FDA OKs its PI3K drug Aliqopa for re­lapsed fol­lic­u­lar lym­phoma pa­tients

A lit­tle more than a year ago, Gilead ran in­to some se­ri­ous prob­lems when its PI3K can­cer pill Zy­delig was linked with a rash of deaths in front­line stud­ies, crip­pling what was once con­sid­ered a po­ten­tial block­buster sales ef­fort. Now Bay­er is com­ing along with an in­fused ri­val that will try and start to fol­low up on the suc­cess en­joyed by John­son & John­son $JNJ and Ab­b­Vie’s $AB­BV Im­bru­vi­ca, a po­ten­tial mega-block­buster play­er which has been scor­ing some big gains in leukemia and lym­phoma.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER